400
Participants
Start Date
February 21, 2023
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2027
Domvanalimab
Administered as specified in the treatment arm
Quemliclustat
Administered as specified in the treatment arm
Zimberelimab
Administered as specified in the treatment arm
Docetaxel
Administered as specified in the treatment arm
Platinum-Based Doublet
Administered as specified in the treatment arm
Mackey Memorial Hospital, Taipei
E-DA Healthcare Group E-DA Hospital, Kaoshiung
Pindara Private Hospital, Benowa
Cancer Research SA Pty Ltd, Adelaide
Sir Charles Gairdner Hospital, Nedlands
Hospital de la Santa Creu i Sant Pau, Barcelona
Hospital Universitari Mutua Terrassa, Barcelona
Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare, New Taipei City
Chungbuk National University Hospital, Cheongju-si
Florida Cancer Specialists (Administration and Drug Shipment), The Villages
Memorial Cancer Institute at Memorial Regional Hospital, Hollywood
CHU Bordeaux Centre Francois Magendie Hôpital du Haut Lévèque, Bordeaux
Hematology Oncology Associates Of The Treasure Coast, Port Saint Lucie
Complejo Hospitalario Universitario Insular Materno Infantil De Gran Canaria, Las Palmas de Gran Canaria
Istituto Oncologico Veneto IRCCS, Padua
University of Alabama at Birmingham (UAB), Birmingham
Hospital Universitario De La Virgen De Valme, Seville
Hospital Universitario Virgen Macarena, Seville
Hospital 9 de Octubre Vithas Valencia, Valencia
Hospital Universitario y Politécnico la Fe, Valencia
Henry Ford Hospital, Detroit
Chonam National University Hwasun Hospital, Hwasun-gun
Northwestern Memorial Hospital, Chicago
Institut De Cancerologie Strasbourg Europe ICANS, Strasboug
Hospices Civils de Lyon Centre Hospitalier Lyon Sud, Lyon
Ochsner Clinic Foundation, Jefferson
University of California San Diego (UCSD), La Jolla
Medical Oncology Associated, PS (dba Summit Cancer Centers), Spokane
The Border Cancer Hospital, Albury
Hopital FOCH, Suresnes
LTD High Technology Hospital Medcenter, Batumi
Caucasus Medical Center, Tbilisi
Israel Georgian Medical Research Clinic Healthycore, Tbilisi
JSC K. Eristavi National Center of Experimental and Clinical Surgery, Tbilisi
Ltd Pineo Medical Ecosystem, Tbilisi
Istituto Romagnolo per lo Studio dei Tumori-Dino Amadori - IRST, Meldola
stituto Nazionale per lo Studio e la Cura dei Tumori, Milan
Azienda Sanitaria Territoriale Pesaro Urbino (AST PU), Pesaro
Fondazione IRCCS Istituto Nazionale dei tumori di Milano, Rome
Szpitale Pomorskie sp. z o.o, Gdynia
Uniwersyteckie Centrum Kliniczne, im. prof. K. Gibińskiego, Katowice
Medpolonia Sp. Z.o.o., Poznan
Centrum Onkologii - Instytut im. Marii Sk?odowskiej-Curie, Warsaw
Samsung Changwon Hospital, Changwon-Si
UOMI Cancer Centre, Barcelona
Hospital Universitario Lucus Augusti, Lugo
Hospital Quirónsalud Málaga, Málaga
National Taiwan University Hospital Yumlin Branch, Yunlin County
Korea University Guro Hospital, Seoul
Asan Medical Center, Seoul
Barts Health NHS Trust St Bartholomew's Hospital, London
Lead Sponsor
Collaborators (1)
Arcus Biosciences, Inc.
INDUSTRY
Gilead Sciences
INDUSTRY